Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

Dexamethasone 8Lenalidomide 4dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3auricularum 3Calcium Dobesilate 3Bortezomib 3pomalidomide 2ixazomib 2filanesib 2Steroids 2Radiotherapy 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2silmitasertib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1milatuzumab 1cc-486 1carfilzomib 1Thalidomide 1Specimen Handling 1Sodium Selenite 1Radiation 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmacytoma × milatuzumab × Plasma cell × Clear all
NCT00421525 2021-08-16

Phase I/II Study of hLL1 in Multiple Myeloma

Gilead Sciences

Phase 1/2 Completed
25 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡